Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas

Laboratory Investigation

Volumn 85, Issue 2, 2005, Pages 165-175

  Nakamura, Mitsutoshi ^a   Ishida, Eiwa ^a   Shimada, Keiji ^a   Kishi, Munehiro ^a   Nakase, Hiroyuki ^a   Sakaki, Toshisuke ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

22q LOH; Primary glioblastoma; Progression; Secondary glioblastoma; TIMP 3

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; CANCER GROWTH; CHROMOSOME 22Q; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE LOCUS; GENE MAPPING; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; ALLELES; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 22; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM METASTASIS; NEOPLASM STAGING; PHYSICAL CHROMOSOME MAPPING; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 13444269098     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700223     Document Type: Article

References (41)

1. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System. International Agency for Research on Cancer (IARC Press): Lyon, 2000.
2. Lang FF, Miller DC, Koslow M, et al. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427-436.
3. Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-223; discussion 223-214.
4. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26.
5. Tohma Y, Gratas C, Biernat W, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:684-689.
6. Fujisawa H, Reis RM, Nakamura M, et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72.
7. Nakamura M, Yang F, Fujisawa H, et al. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 2000;59:539-543.
8. Nakamura M, Yonekawa Y, Kleihues P, et al. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001;81:77-82.
9. Wild A, Langer P, Celik I, et al. Chromosome 22q in pancreatic endocrine tumors: identification of a homozygous deletion and potential prognostic associations of allelic deletions. Eur J Endocrinol 2002;147:507-513.
10. Iida A, Kurose K, Isobe R, et al. Mapping of a new target region of allelic loss to a 2-cM interval at 22q13.1 in primary breast cancer. Genes Chromosomes Cancer 1998;21:108-112.
11. Allione F, Eisinger F, Parc P, et al. Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. Int J Cancer 1998;75:181-186.
12. Ino Y, Silver JS, Blazejewski L, et al. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol 1999;58:881-885.
13. Oskam NT, Bijleveld EH, Hulsebos TJ. A region of common deletion in 22q13.3 in human glioma associated with astrocytoma progression. Int J Cancer 2000;85:336-339.
14. Hartmann C, Numann A, Mueller W, et al. Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. Int J Cancer 2004;108:839-844.
15. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988;318:684-688.
16. Jacoby LB, MacCollin M, Louis DN, et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-419.
17. Ueki K, Wen-Bin C, Narita Y, et al. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 1999;59:5995-5998.
18. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 1999;155:627-632.
19. Rubio MP, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 1994;54:45-47.
20. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-206.
21. Sevenet N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 1999;8:2359-2368.
22. Weber M, Stockhammer F, Schmitz U, et al. A mutational analysis of INI1 in sporadic human brain tumors. Acta Neuropathol (Berl) 2001;101:479-482.
23. Nakamura M, Watanabe T, Yonekawa Y, et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001;22:1715-1719.
24. Dunham I, Shimizu N, Roe BA, et al. The DNA sequence of human chromosome 22. Nature 1999;402:489-495.
25. Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor Loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003;63:737-741.
26. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
27. INK4a genes in primary central nervous system lymphomas. Cancer Res 2001;61:6335-6339.
28. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-168.
29. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.
30. Kao HT, Porton B, Czernik AJ, et al. A third member of the synapsin gene family. Proc Natl Acad Sci USA 1998;95:4667-4672.
31. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
32. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998;58:2310-2315.
33. Qi JH, Ebrahem Q, Moore N, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003;9:407-415.
34. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802-1808.
35. von Deimling A, Fimmers R, Schmidt MC, et al. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 2000;59:544-558.
36. Castells A, Gusella JF, Ramesh V, et al. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 2000;60:2836-2839.
37. Reis PP, Rogatto SR, Kowalski LP, et al. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene 2002;21:6480-6487.
38. Lin H, Pizer ES, Morin PJ. A frequent deletion polymorphism on chromosome 22q13 identified by representational difference analysis of ovarian cancer. Genomics 2000;69:391-394.
39. Miyakawa A, Wang XL, Nakanishi H, et al. Allelic loss on chromosome 22 in oral cancer: possibility of the existence of a tumor suppressor gene on 22q13. Int J Oncol 1998;13:705-709.
40. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001;28:220-221.
41. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000;24:300-303.